The authors are retracting this Article. The Article comprises three parts: a case-control study; a meta-analysis of case-control studies; and Mendelian randomization (MR) analyses (two datasets; a Japanese dataset and a public genome-wide association study [GWAS]-pooled dataset). In the MR analysis using the public dataset, the authors mistook effect alleles, resulting in incorrect results (Figure 3) and conclusion.
Our updated MR results are as follows: odds ratio (OR)scz/crp 0.87 (95% CI 0.76–1.00, p = 0.046) using rs2794520; 0.83 (95% CI 0.72–0.96, p = 0.014) using rs1183910; 0.85 (95% CI 0.77–0.94, p = 0.0017) across these two single nucleotide polymorphisms (SNPs); and 0.89 (95% CI 0.82–0.97, p = 0.006) using 15 C-reactive protein (CRP)-associated SNPs, which reached genome-wide significance in a meta-analysis of GWAS, respectively. These updated results of the MR analysis using the limited number of SNPs indicate a protective causal association between elevated CRP levels and schizophrenia risk. Therefore, the hypothesis in the conclusion of the Article—that medications which reduce CRP levels can be used in schizophrenia—is not supported.
All authors recognize these miscalculations in the original MR analysis and have agreed to the retraction of this Article.
The online version of the original article can be found at https://doi.org/10.1038/srep26105
About this article
Cite this article
Inoshita, M., Numata, S., Tajima, A. et al. Retraction Note: A significant causal association between C-reactive protein levels and schizophrenia. Sci Rep 8, 46947 (2018). https://doi.org/10.1038/srep46947
This article is cited by
Mendel’s laws, Mendelian randomization and causal inference in observational data: substantive and nomenclatural issues
European Journal of Epidemiology (2020)
BMC Medicine (2019)
Nature Immunology (2018)